Benign prostatic hyperplasia and prostate cancer: An overview for primary care physicians

International Journal of Clinical Practice

Volumn 64, Issue 13, 2010, Pages 1740-1745

  Sausville, J ^a   Naslund, M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BICALUTAMIDE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; GONADORELIN DERIVATIVE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ANTICOAGULANT THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; CRYOTHERAPY; DIGITAL RECTAL EXAMINATION; DIZZINESS; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; HEMOSTASIS; HIGH INTENSITY FOCUSED ULTRASOUND; HOLMIUM LASER; HUMAN; HYPERTHERMIC THERAPY; IMPAIRED BLADDER EMPTYING; LASER SURGERY; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MINIMALLY INVASIVE PROCEDURE; NOCTURIA; ORCHIECTOMY; ORTHOSTATIC HYPOTENSION; PHYSICIAN; POSTVOID RESIDUAL URINE VOLUME; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY; RETROGRADE EJACULATION; REVIEW; ROBOTICS; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URINALYSIS; URINARY URGENCY; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; LASER THERAPY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATISM; RISK FACTORS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 78649233695     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02534.x     Document Type: Review

References (58)

1. Roehrborn CG, McConnell JD,. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In:, Wein AJ, et al., eds. Campbell-Walsh Urology, 9th edn. Philadelphia, PA: Saunders Elsevier, 2007: 2727 - 65.
2. Mochtar CA, Kiemeney LA, Van Riemsdjik MM, Laguna MP, Debruyne FM, De La Rosette JJ,. Post-void residual urine is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol 2006; 175: 213 - 6.
3. Roehrborn CG,. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008; 101 (S3): 17 - 21.
4. Emberton M,. Definition of at-risk patients: dynamic variables. BJU Int 2006; 97 (S2): 12 - 5.
5. Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, Ohl DA,. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007; 61: 1535 - 6.
6. McConnell JD, Roehrborn CG, Bautista OM, et al. The long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387 - 98.
7. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM,. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163: 107 - 13.
8. Rosenberg MT, Miner MM, Riley PA, Staskin DR,. STEP: Simplified treatment of the enlarged prostate. Int J Clin Pract 2010; 64: 488 - 96.
9. McConnel JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557 - 63.
10. Roehrborn C.G., Siami P., Barkin J., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: four-year results from the CombAT study. Eur Urol 2010; 57: 123 - 31.
11. Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol 2008; 180: 1030 - 2.
12. Kirby R, Lepor H, Evaluation and nonsurgical management of benign prostatic hyperplasia. In:, Wein AJ, et al., eds. Campbell-Walsh Urology, 9th edn. Philadelphia, PA: Saunders Elsevier, 2007: 2766 - 802.
13. Thiel DD, Petrou SP,. Electroresection and open surgery. Urol Clin N Am 2009; 36: 461 - 70.
14. Wosnitzer MS, Rutman MP,. KTP/LBO laser vaporization of the prostate. Urol Clin N Am 2009; 36: 471 - 83.
15. Naspro R, Bachmann A, Gilling P, et al. A review of the recent evidence (2006-2008) for 532-nm photoselective vaporization and holmium laser enucleation of the prostate. Eur Urol 2009; 55: 1345 - 57.
16. Sandhu JS, Ng CK, Gonzalez RR, Kaplan SA, Te AE,. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 2005; 19: 1196 - 8.
17. Kavoussi PK, Hermans MR,. Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hyperplasia. J Sex Med 2008; 5: 2669 - 71.
18. Klein EA, Platz EA, Thompson IM, Epidemiology, Etiology, and Prevention of Prostate Cancer. In:, Wein AJ, et al., eds. Campbell-Walsh Urology, 9th edn. Philadelphia, PA: Saunders Elsevier, 2007: 2854 - 73.
19. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325 - 9.
20. Hernandez J, Thompson IM,. Prostate-specific antigen:a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894 - 904.
21. Kodak JA, Mann DL, Klyushnenkova EN, Alexander RB,. Activation of innate immunity by prostate specific antigen (PSA). Prostate 2006; 66: 1592 - 9.
22. Chu KC, Tarone RE, Freeman HP,. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003; 97: 1507 - 16.
23. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≥ 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239 - 46.
24. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860 - 4.
25. Schröder FH, Carter HB, Wolters T, et al. Early detection of prostate cancer in 2007 part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 469 - 77.
26. Carter HB, Pearson JD, Waclawiw Z, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45: 591 - 6.
27. Gretzer MB, Partin AW,. Prostate cancer tumor markers. In:, Wein AJ, et al., eds. Campbell-Walsh Urology, 9th edn. Philadelphia, PA: Saunders Elsevier, 2007: 2896 - 911.
28. Loeb S, Catalona WJ,. Prostate-specific antigen in clinical practice. Cancer Lett 2007; 249: 30 - 9.
29. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G,. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434 - 41.
30. Klein LT, Lowe FC,. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin N Am 1997; 24: 293.
31. Schröder FH, Van Der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998; 90: 1817.
32. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310 - 9.
33. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868 - 78.
34. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320 - 8.
35. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 963 - 9.
36. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185 - 91.
37. Carroll PC, Albertsen PC, Greene K, et al. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Online
38. Bangma CH, Roobol MJ, Steyerberg EW,. Predictive models in diagnosing indolent cancer. Cancer 2009; 115: 3100 - 6.
39. Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB,. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183: 1779 - 85.
40. Graham J, Baker M, Macbeth F, Titshall V,. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 2008; 336: 610 - 2.
41. Van den Bergh RC, Essink-Bot ML, Roobol MJ, Schroeder FH, Bangma CH, Steyerberg EW,. Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol 2010; 183: 1786 - 91.
42. Walsh PC,. The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. J Urol 2007; 177: 1632 - 5.
43. Lepor H,. Status of radical prostatectomy in 2009: is there medical evidence to justify the robotic approach? Rev Urol 2009; 11: 61 - 70.
44. Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL,. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 2008; 26: 2278 - 84.
45. Ficarra V, Novara G, Artibani W, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009; 55: 1037 - 63.
46. Bhojani M, Capitanio U, Suardi N, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys 2010; 76: 342 - 8.
47. Bolla M, De Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516 - 27.
48. Stock RG, Stone NN,. Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy. Urol Clin N Am 2010; 37: 83 - 96.
49. Pieters BR, De Back DZ, Koning CC, Zwinderman AH,. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009; 93: 168 - 73.
50. Rove KO, Sullivan KF, Crawford ED,. High-intensity focused ultrasound: ready for primetime. Urol Clin N Am 2010; 37: 27 - 35.
51. Finley DS, Pouliot F, Miller DC, Belldegrun AS,. Primary and salvage cryotherapy for prostate cancer. Urol Clin N Am 2010; 37: 67 - 82.
52. Ahmed HU, Zacharakis E, Dudderidge T, et al. High intensity focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 2009; 101: 19 - 26.
53. Challacombe BJ, Murphy DG, Zakri R, Cahill DJ,. High intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. BJU Int 2009; 104: 200 - 4.
54. Shelley M, Wilt TJ, Coles B, Mason MD,. Cryotherapy for localized prostate cancer. Cochrane Database Syst Rev 2007; 18.
55. Malcolm JB, Fabrizio MD, Barone BB, et al. Quality of life after open or robotic prostatectomy, cryoablation, or brachytherapy for localized prostate cancer. J Urol 2010; 183: 1822 - 8.
56. Huggins C,. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942; 115: 1192 - 200.
57. Attard G, Reid AHM, Olmos D, De Bono JS,. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009; 69: 4937 - 40.
58. Sausville EA, Longo DL,. Principles of cancer treatment. In:, Fauci AS, et al., eds. Harrison's Principles of Internal Medicine, 17th edn. New York, NY: McGraw-Hill, 2008: 464 - 82.